C-C chemokine receptor type 9 is a protein that in humans is encoded by the CCR9 gene. [5] [6] This gene is mapped to the chemokine receptor gene cluster region. Two alternatively spliced transcript variants have been described. [6] CCR9 has also recently been designated CDw199 (cluster of differentiation w199).

2024年1月19日 · CC族趋化因子受体9（CC chemokine receptor 9，CCR9）属于趋化因子受体家族中的一员，是具有7次跨膜结构的G蛋白偶联受体。 趋化因子受体家族是一类重要的细胞表面受体，与趋化因子结合后可以调控细胞的运动、分化、增殖等多种功能。 趋化因子受体可分为四个亚家族，分别是CC、CXC、CX3C和C型。 其中CCR9属于CC亚家族（点击查看趋化因子家族介绍）。 CCR9由转录物A（369个氨基酸，42 kDa）和转录物B（357个氨基酸，40.8 kDa）组 …

针对一系列疾病靶点的研究机理， BioMice百奥动物 自主开发了 CCR家族 靶点人源化小鼠，包括CCR1-CCR9，可以为该靶点药物的开发提供有效的临床前药效评价工具，助力靶向药物研究。

Multiple studies have confirmed that chemokine receptor 9 (CCR9) and its exclusive ligand, chemokine 25 (CCL25), are overexpressed in a variety of malignant tumors and are closely associated with tumor proliferation, apoptosis, invasion, migration and drug resistance.

趋化因子配体25（ccl25）和趋化因子受体9（ccr9）是白细胞和癌细胞中迁移，增殖和凋亡的重要调节剂。已经证明阻断ccr9 / ccl25信号是潜在的新型癌症疗法。对ccr9和ccl25的研究揭示了它们相关的上游和下游信号通路。

2024年12月24日 · CCR9 (C-C Motif Chemokine Receptor 9) is a Protein Coding gene. Diseases associated with CCR9 include Ileitis and Celiac Disease. Among its related pathways are Class A/1 (Rhodopsin-like receptors) and GPCR downstream signalling.

2016年2月16日 · This review will examine the expression of CCR9 in cancer, recent insights into the mechanisms of CCL25/CCR9 that are involved in tumor chemoresistance and metastasis, and the potential application of CCR9-based targeted therapy.

2021年8月18日 · CCR9 is mainly distributed in immature T lymphocytes and intestinal cells surface, and after binding to its specific ligands, plays a key role in T lymphocyte development and tissue-specific homing (Wermers et al., 2011; Wu et al., 2014).

该基因编码的蛋白质是一种 G 蛋白偶联受体，具有七个跨膜结构域，属于 β 趋化因子受体家族。 趋化因子及其受体是正常和炎症条件下胸腺细胞迁移和成熟的关键调节因子。 该基因在小肠和结肠的 T 淋巴细胞中差异表达，其与趋化因子 25 的相互作用有助于小肠上皮内淋巴细胞归巢。 这表明该基因在指导对胃肠道不同部分的免疫反应中的作用。 该基因及其专属配体趋化因子 25 在多种恶性肿瘤中过表达，与肿瘤增殖、凋亡、侵袭、迁移和耐药密切相关。 该基因映射到趋化因子 …

2016年2月16日 · The structures of chemokine receptor 9 (CCR9) and its specific ligand chemokine ligand 25 (CCL25) have been elucidated, and, interestingly, a number of studies have demonstrated that CCR9 is a potential tumor biomarker in diagnosis and therapy, as it has been found to be highly expressed in a wide range of cancers.